Fenofibric Acid Interactions

Brand names: Fenofibric Acid

Peroxisome Proliferator Receptor alpha Agonist

Route: Oral

Contraindications

4 CONTRAINDICATIONS Fenofibric acid delayed-release capsules are contraindicated in patients with: Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis [see Clinical Pharmacology ( 12.3 )] . Active liver disease, including those with unexplained persistent liver function abnormalities [see Warnings and Precautions ( 5.2 )] . Pre-existing gallbladder disease [see Warnings and Precautions ( 5.5 )] . Hypersensitivity to fenofibric acid, fenofibrate, or any of the excipients in fenofibric acid delayed-release capsules. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with fenofibrate [see Warnings and Precautions ( 5.9 )] . Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis ( 4 ). Active liver disease including those with unexplained persistent liver function abnormalities ( 4 ). Pre-existing gallbladder disease ( 4 ). Hypersensitivity to fenofibric acid, fenofibrate, or any of the excipients in fenofibric acid delayed-release capsules ( 4 , 5.9 ).

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no evidence of embryo-fetal toxicity was observed with oral administration of fenofibrate in rats and rabbits during organogenesis at doses less than or comparable to the maximum recommended clinical dosage of 135 mg of fenofibric acid delayed-release capsules daily, based on body surface area (mg/m 2 ). Adverse reproductive outcomes occurred at higher doses in the presence of maternal toxicity (see Data). Fenofibric acid delayed-release capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In pregnant rats given oral dietary doses of 14 mg/kg/day, 127 mg/kg/day, and 361 mg/kg/day from gestation day 6 to 15 during the period of organogenesis, no adverse developmental findings were observed at 14 mg/kg/day (less than the clinical exposure at the maximum recommended human dose [MRHD] of 300 mg fenofibrate daily, comparable to 135 mg fenofibric acid delayed-release capsules daily, based on body surface area comparisons). Increased fetal skeletal malformations were observed at maternally toxic doses (361 mg/kg/day, corresponding to 12 times the clinical exposure at the MRHD) that significantly suppressed maternal body weight gain. In pregnant rabbits given oral gavage doses of 15 mg/kg/day, 150 mg/kg/day, and 300 mg/kg/day from gestation day 6 to 18 during the period of organogenesis and allowed to deliver, no adverse developmental findings were observed at 15 mg/kg

7 interactions on record

Cases of myopathy and rhabdomyolysis reported with concomitant use. Monitor patients for signs and symptoms of myopathy during initiation and dosage titration of colchicine.

Source: NLP:fenofibric acid

Immunosuppressant can produce nephrotoxicity and decreased creatinine clearance, increasing risk of renal function deterioration with fenofibric acid. Monitor renal function and use lowest effective dosage.

Source: NLP:fenofibric acid

Fibrates may potentiate coumarin anticoagulant effects with prolongation of PT/INR. Reduce anticoagulant dosage and monitor PT/INR frequently to prevent bleeding complications.

Source: NLP:fenofibric acid

Fibrates may increase risk of myopathy and rhabdomyolysis when used concomitantly with statins. Monitor patients for signs and symptoms of myopathy during initiation and dosage titration.

Source: NLP:fenofibric acid

Immunosuppressant can produce nephrotoxicity and decreased creatinine clearance, increasing risk of renal function deterioration with fenofibric acid. Monitor renal function and use lowest effective dosage.

Source: NLP:fenofibric acid

Bile acid binding resins may impede fenofibric acid absorption. Separate dosing by at least 1 hour before or 4-6 hours after resin administration.

Source: NLP:fenofibric acid

Bile-acid binding resins may bind fenofibric acid concurrently. Administer fenofibric acid at least 1 hour before or 4-6 hours after the bile acid resin to avoid impeding absorption.

Source: NLP:fenofibric acid